FEMARA Drug Patent Profile

When do Femara patents expire, and what generic alternatives are available?

Femara is a drug marketed by Novartis Pharms and is included in one NDA.

The generic ingredient in FEMARA is letrozole. There are twenty-four drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the letrozole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Femara

A generic version of FEMARA was approved as letrozole by ACCORD HLTHCARE on June 3^rd, 2011.

Summary for FEMARA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	199
Drug Prices:	Drug price information for FEMARA
What excipients (inactive ingredients) are in FEMARA?	FEMARA excipients list
DailyMed Link:	FEMARA at DailyMed

See drug prices for FEMARA

Recent Clinical Trials for FEMARA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rovi Pharmaceuticals Laboratories	PHASE3
Verastem, Inc.	Phase 3
GOG Foundation	Phase 3

See all FEMARA clinical trials

Pharmacology for FEMARA

Drug Class	Aromatase Inhibitor
Mechanism of Action	Aromatase Inhibitors

Paragraph IV (Patent) Challenges for FEMARA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FEMARA	Tablets	letrozole	2.5 mg	020726	1	2006-03-02

US Patents and Regulatory Information for FEMARA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms	FEMARA	letrozole	TABLET;ORAL	020726-001	Jul 25, 1997	AB	RX	Yes	Yes

Expired US Patents for FEMARA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms	FEMARA	letrozole	TABLET;ORAL	020726-001	Jul 25, 1997

International Patents for FEMARA

See the table below for patents covering FEMARA around the world.

Country	Patent Number	Title	Estimated Expiration
Slovakia	279102
Cyprus	1905	Alpha-heterocycle substituted tolunitriles
Denmark	172190
Algeria	1055	Tolunitriles substitués par des alpha hétérocycles.
Slovakia	279103
Romania	101532	SUBSTITUTED HETEROCYCLIC TOLUNITRILE DERIVATIVES PREPAPATION METHOD
South Korea	910000482

Supplementary Protection Certificates for FEMARA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0236940	SPC/GB97/013	United Kingdom		PRODUCT NAME: LETROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: FR 341 474-2 19960724; FR 341 475-9 19960724; UK PL00001/0224 19961118
0236940	C970011	Netherlands		PRODUCT NAME: LETROZOLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT; NAT. REGISTRATION: RVG 20755 19970106; FIRST REGISTRATION: FR NL 21 881 19960724
0236940	97C0053	Belgium		PRODUCT NAME: LETROZOLE; NAT. REGISTRATION NO/DATE: 206 IS 241 F 3 19970616; FIRST REGISTRATION: FR 341 474.2 1996072

Market Dynamics and Financial Trajectory of Femara (Letrozole)

Last updated: March 30, 2026

What is Femara and how is it positioned within the pharmaceutical landscape?

Femara (letrozole) is an aromatase inhibitor approved primarily for breast cancer treatment. It is indicated for hormone receptor-positive early and metastatic breast cancer in postmenopausal women. Developed by Novartis, Femara has been a key drug in oncology since its FDA approval in 1997.

What are the current market sizes and growth trends?

The global breast cancer therapeutics market was valued at approximately USD 19 billion in 2021 and is projected to reach USD 32 billion by 2028, exhibiting a CAGR of 7.1% (Research and Markets, 2022). Femara accounts for a significant share within this segment, especially in hormonal therapy.

Revenue estimates and sales trends

• 2019: Estimated global sales of Femara at USD 1.2 billion.
• 2020: Slight decline to USD 1.1 billion attributable to pandemic-related disruptions.
• 2021: Recovery to USD 1.3 billion, with growth driven by worldwide adoption.
• 2022: Approximate sales reach USD 1.4 billion, with projections to stabilize around USD 1.4–1.6 billion annually through 2025.

Regional sales distribution

Region	2021 Sales (USD million)	Share (%)
North America	700	54%
Europe	325	25%
Asia-Pacific	195	15%
Rest of the World	85	6%

North America remains the largest market, with Europe as a close second. Adoption rates in Asia-Pacific are increasing, attributed to expanding healthcare infrastructures.

How do patent status and generics influence the market?

The original patent for Femara expired in Europe in 2014 and in the US in 2015. Subsequent generic versions have entered the market, leading to significant price competition:

• Price reductions: Generics are priced approximately 50–70% lower than branded Femara.
• Market share: Generics hold roughly 70% of sales in regions where patents have expired.
• Impact on Novartis: Revenue from Femara has declined post-patent expiry, but brand retained a premium share through branding and physician preferences.

What is the competitive landscape?

Major competitors include:

• Aromatase inhibitors:
  • Anastrozole (Arimidex, AstraZeneca)
  • Exemestane (Aromasin, Pfizer)
• Selective ER modulators:
  • Tamoxifen (Nolvadex, AstraZeneca)

The competitive advantage for Femara hinges on its higher efficacy in some settings, such as extended adjuvant therapy, and perceived better tolerability.

What are the regulatory and pipeline considerations?

• Regulatory approvals: Femara is approved in over 100 countries.
• Pipeline developments:
  • Research into new indications, including ovarian stimulation and other hormone-related cancers.
  • Combination therapies with CDK4/6 inhibitors and immunotherapies.
  • Biosimilars are unlikely, since Femara is a small molecule, but generic versions will continue to enter markets.

What are the key financial risks and opportunities?

Risks

• Patent expirations reduce exclusivity revenue.
• Market saturation in developed regions.
• Pricing pressures from generics and healthcare policies.

Opportunities

• Expansion into emerging markets.
• Increase in off-label uses and combination regimens.
• Development of next-generation aromatase inhibitors with improved safety profiles.

How will market dynamics evolve?

The oncology drug market is trending toward personalized medicine. Femara's role is expected to diminish in favor of newer agents in combination therapy but will maintain relevance in established treatment protocols. Global market expansion, especially in Asia-Pacific, offers growth prospects despite pricing pressures.

Summing up: key financial indicators

Metric	2021 Data	Comments
Estimated global sales	USD 1.3 billion	Slight recovery post-pandemic
Retail price (average)	USD 60–150 per treatment cycle	Price varies by region and formulation
Patent status	Expired in US (2015), EU (2014)	Key driver for generics entry
Expected CAGR (2022–2025)	3–5%	Driven by emerging markets and combination therapies

Key Takeaways

• Femara remains a leading hormonal therapy for breast cancer, with steady revenue streams, but faces decline due to patent expiry and generic competition.
• Market expansion in Asia-Pacific provides future growth potential.
• Patent loss has heightened price competition, reducing margins but also widening access.
• The drug's role in combination therapies and new indications could sustain its relevance.
• The shift towards personalized treatment reduces the dominance of existing aromatase inhibitors over time.

FAQs

1. What is the primary driver of Femara’s revenue decline?
Patent expiration and subsequent entry of cheaper generic versions limit market exclusivity and reduce branded sales.

2. How competitive is Femara compared to its main rivals?
Femara is considered effective but faces stiff competition from anastrozole and exemestane, which often offer similar efficacy at lower costs post-generic entry.

3. Are there significant opportunities in emerging markets?
Yes, expanding healthcare infrastructure and rising breast cancer prevalence support growth in regions like China, India, and Southeast Asia.

4. What impact do biosimilars have on the aromatase inhibitor market?
Biosimilars are unlikely because Femara is a non-biologic small molecule. However, generic versions act as de facto biosimilars for price competition.

5. Will Femara’s role diminish with newer therapies?
While newer targeted therapies are emerging, Femara remains a standard in hormone receptor-positive breast cancer, especially in less advanced settings.

---

Sources

[1] Research and Markets. (2022). Global Breast Cancer Therapeutics Market Size, Share & Trends Analysis Report.

[2] FDA. (2015). Femara (Letrozole) Prescribing Information.

[3] Novartis. (2022). Femara Product Information.

[4] IMS Health. (2021). Pharmaceutical Market Trends.